[The best in 2000 on heart failure].

Area of Science:

• Cardiology
• Pathology
• Genetics

Context:

• Cardiac failure research in 2000 encompassed diverse pathological fields.
• Epidemiological data for cardiac failure in France and Europe were updated.
• Significant advancements were made across various aspects of cardiac failure.

Purpose:

• To review and summarize key advancements in cardiac failure during the year 2000.
• To highlight new findings in epidemiology, diagnostics, and therapeutics for cardiac failure.
• To underscore the evolving understanding of cardiac failure's etiology and management.

Summary:

• The implantable defibrillator's role in preventing sudden death in hypertrophic cardiomyopathy was confirmed.
• The prognostic significance of etiology in dilated cardiomyopathy was established, and acute fulminating viral myocarditis was identified as a distinct entity.
• New genetic abnormalities in dilated cardiomyopathy were discovered, and type B natriuretic peptide emerged as a key biomarker for diagnosis, prognosis, and treatment (nesiritide).
• Beta-blockers were confirmed effective, even in severe cardiac failure.
• Biventricular stimulation offered a new therapeutic option for advanced cardiac failure.
• The first cellular transplantation by a French team marked a significant milestone.

Impact:

• These advancements refined the diagnosis and prognosis of various cardiac failure types.
• Therapeutic strategies were enhanced with confirmed roles for beta-blockers and new options like biventricular stimulation.
• The identification of genetic factors and novel biomarkers like type B natriuretic peptide opens avenues for personalized medicine.
• Pioneering cellular transplantation research offers future hope for cardiac regeneration.